



Manuscript ID

ZUMJ-2203-2492 (R2)

DOI

10.21608/zumj.2022.125953.2492

**REVIEW ARTICLE**

## Mechanism of Actions of Some Common Toxic Agents Causing Toxic Cardiomyopathy

Abdelazem Khaled, Meriet Ahmed Mohamed, Ahmed Hamdy Gheith, Hala Mohamed, Goda Ibrahim Abdellatif, Rana Fouad, Abdulrahman Mohamed Tantawy, Ereney Melad, Haitham Magdy, Youssef Hesham Elkordi\*, Ahmed Adel Mohamed

Undergraduate medical student, Faculty of Medicine, Zagazig University, Zagazig, Egypt

**\*Corresponding**

**Author:**

Youssef Hesham Elkordi  
Faculty of Medicine,  
Zagazig University,  
Zagazig, Egypt.  
E-mail:  
yf.ki2000@gmail.com

Submit Date 2022-03-11

Revise Date 2022-04-06

Accept Date 2022-04-07

### ABSTRACT

**Background:** Toxic cardiomyopathy is related to heart failure in many cases and may lead to death. We focused on the mechanisms by which some common toxic agents cause cardiomyopathy. We searched in articles, case reports, experimental and clinical studies on this topic

Our results have shown that the heart or the cardiovascular system is one of the most affected systems by toxic agents. We summarized studies which mentioned some common cause such as; "Anti-cancer drugs", "Anti-diabetic drugs", "Cocaine", "Ethanol", "Heavy Metals", and "Digitalis drugs" and their mechanism of action inducing cardiotoxicity. We concluded that mechanisms underlying toxic cardiomyopathy are complicated and variable. However, they generally include disruption of cell bioenergetics and intracellular calcium handling. It is also involved in: production of reactive oxygen species (ROS), development of oxidative stress and apoptosis induction. **Conclusions:** Toxic agents have a very harmful effect on the heart producing cardiomyopathy and heart failure. A lot of drugs and environmental toxins can produce cardiotoxicity including; anti-cancer drugs, anti-diabetic drugs, cocaine, ethanol, CO, and heavy metals their mechanisms of action are complicated and included many factors.



**Keywords:** Cardiomyopathy; Toxicity; Heart Failure; Toxic agent; Digitalis

### INTRODUCTION

Cardiomyopathy is usually defined as any condition that causes primary ventricular or electrical cardiac dysfunction, that is not secondary to any other forms of cardiac dysfunction (Ex.: ischemia, volume-pressure overload, etc...) [1]. These conditions are frequently genetic [1], however, in some cases, cardiomyopathy can be caused by toxins. The true prevalence of toxin-induced cardiomyopathy is unknown. However, it is common in patients receiving chemotherapy [2]. In addition, a lot of diabetic patients receiving pharmacological therapy develops severe cardiovascular manifestations [3].

Therefore, the aim of this review article is to present the effect of these toxic agents on the heart and to explain the mechanism by which these toxins can cause cardiomyopathy and myocardial dysfunction. In this article, we will focus on: anti-cancer drugs, anti-diabetic drugs, cocaine, ethanol, carbon monoxide, various types

of heavy metals, scorpion venom and finally the toxicity of digitalis drug and their mechanism of action.

#### Anticancer drugs

Cardiomyopathy is an adverse effect of anticancer drug therapy. Although the efficacy of anticancer treatments has improved, long-term outcomes are altered by the development of cardiotoxicity [4].

##### 1-Anthracyclines:

Doxorubicin is a category of anti-neoplastic drugs extensively used in management of many malignancies. The mechanism of anthracycline-prompted cardiomyopathy has been studied, and of the many mechanisms proposed, free radical-mediated oxidative damage to the cardiac myocyte, with membrane lipid peroxidation and mitochondrial dysfunction have been suggested to be the most common mechanism [5].

##### 2-Monoclonal antibodies:

Trastuzumab is a monoclonal antibody to human epidermal growth factor receptor type 2 [6]. Trastuzumab and anthracyclines are suggested

to mediate cardiotoxicity via different pathways. The available lines of evidence suggest that trastuzumab can exacerbate the cardiotoxic effects of anthracyclines and thus, prior exposure to anthracyclines is regarded as one of the risk factors for trastuzumab-induced cardiotoxicity. Although it is generally believed that the trastuzumab-induced cardiotoxic effects are reversible, various preclinical studies have revealed its apoptotic effects on cardiomyocytes. Thus, the issue of the reversibility of its cardiotoxic effects remains to be fully resolved. The nature of trastuzumab-associated cardiotoxicity is exceedingly exceptional from that of doxorubicin and is called Type II CRCDC which is related to myocyte disorder however now it is no longer associated with irreversible injury[7].

### **3-Cisplatin:**

Cisplatin is one of the alkylating group of broad-spectrum antineoplastic drugs used against many types of tumors [8]. Cisplatin-induced cardiac disorder is associated with mitochondrial membrane depolarization together with ultrastructural abnormalities of the mitochondria. After cisplatin treatment. Cardio myocytes show signs and symptoms of apoptosis in the form of activation of the endoplasmic reticulum strain response, prolonged caspase 3 activity.

### **4-Arsenic trioxide:**

Arsenic trioxide is an anticancer drug, inducing modifications in apoptotic signaling in most cancers cells. scientific reviews have proven that it is related to considerable cardiotoxicity. Exposure of H9C2 cardiomyocytes to clinically applicable concentrations of the drug (2–10  $\mu$ M) showed apoptosis, ROS formation, intracellular calcium overload, and caspase-three activation [9].

### **5-Mitoxantrone:**

Mitoxantrone is a DNA topoisomerase inhibitor and non-anthracycline antineoplastic agent. Cardiomyopathy is induced by long term use of mitoxantrone. In vitro and In vivo studies suggested the possible mechanism is alteration of ATP ranges with hyperpolarization of the mitochondrial membrane potential and changes of intracellular calcium. Another suggested mechanism is inhibition of ATP-synthase expression and with concomitant growth in ROS formation [10, 11].

## **Anti-diabetic Drugs**

### **1-Sulphonylureas:**

Sulphonylureas close ATP-dependent potassium channels, which are responsible for insulinotropic effect and the negative effects on the heart. It has

been reported that sulphonylureas reduce blood flow of the myocardium during resting state which increase the risk for myocardial infarction [12].

### **2-Meglitinides:**

Meglitinides stimulate insulin secretion. These compounds inhibit ATP-dependent potassium channels; however, because of the strong involvement of ATP-dependent potassium channels in the mechanism of action, caution should be present [13].

### **3-Glitazones:**

Glitazones are a special category of anti-diabetic drugs including troglitazone, pioglitazone, and rosiglitazone which have slightly different chemical compositions and modes of action than the other categories. Chemically, they are chroman thiazolidinediones; some analogues are also available [14].

### **4-Oral hypoglycemic drugs**

Biguanides, sulphonylureas, meglitinides, glitazones, and alpha-glucosidase inhibitors have been related to a variety of negative or even fatal cardiovascular events. Sulphonylurea and meglitinides inhibit ATP dependent potassium channels while glitazones are chroman thiazolidinediones

The FDA recommended that to determine the effectiveness of a potential anti-diabetic medication for T2DM, the manufacturers demonstrate that the new drug would not result in an unreasonable increase in cardiovascular risk, as well as the fact that the study population contains patients who are at high risk. Other requirements included trials for at least two years. The gliflozins are currently being investigated for their long-term cardiovascular outcome [15].

### **Cocaine:**

Cocaine is a sympathomimetic drug which has been used illegally as a stimulant and euphoric drug [16]. A lot of cases of cardiomyopathy in cocaine consumers have been reported [17]. Cardiovascular effect of cocaine includes: vasoconstriction of the coronary blood vessels which causes ischemic heart diseases and myocardial infarction. It also causes generalized VC which causes hypertension and organs ischemia [18]. Effect of cocaine on the heart has different mechanisms. It Inhibits reuptake of norepinephrine and dopamine which increases sympathetic effect on the heart increasing its inotropic and chronotropic effects. It also inhibits the transient influx of sodium across the cell membrane leading to release of neurotransmitters which bind to alpha and beta adrenergic receptors leading to its stimulation which activates adenylyl-

cyclase enzyme increasing cAMP which increases calcium influx into myocardial cells increasing force of contraction of myocytes. Elevated systolic calcium can cause sustained depolarization and trigger sustained action potential and extra-systole causing arrhythmias [18]. That may lead to left ventricular dilated cardiomyopathy [19].

#### **Ethanol:**

Alcohol or ethanol is the most toxic agent to be consumed all over the world. It was reported that up to 40% of patients with idiopathic dilated cardiomyopathy are alcohol consumers [20]. Alcohol has many different cardiac effects. They occur as a result of direct exposure of the cardiac tissue to alcohol or its toxic metabolites [21]. One of the most significant mechanisms of cardiac damage is mitochondrial dysfunction as it impairs the mitochondrial membrane decreasing the membrane potential, reducing the enzymatic activity and decreasing ATP synthesis. It also causes oxidative stress increasing ROS production leading to apoptosis [22]. As repair mechanisms; necrosis and excessive fibrosis follow apoptosis which decrease the capability of the myocardial contractility. It also causes disruption of calcium channels causing defects in sarcolemmal contractions. Ventricular hypertrophy and dilatation occur as compensatory mechanisms which will lead to heart failure [21].

#### **Carbon monoxide:**

Carbon monoxide (CO) is an odorless, colorless gas. It can cause organ damage and toxic effects even in small doses [23].

Several effects of CO on the cardiovascular system are well established such as myocardial infarction, arrhythmia, heart failure and pulmonary edema which are caused by ischemic hypoxia[24].

There are several proposed mechanisms to explain CO-induced cardiomyopathy:

(1) A classical explanation is that CO binds with haemoglobin forming carboxyhaemoglobin (COHb) and impairing oxygen delivery to mitochondria which causes hypoxemia and leads to systolic dysfunction. However, the explanation is contradicted by animal studies which shows increased sympathetic stimulation in CO-intoxicated animals leading to increased heart rate and maintained blood pressure [25].

(2) Myocardial stunning due to catecholamine surge caused by acute CO intoxication. [26] High levels of postmortem catecholamines were found in spinal and pericardial fluids in cases of CO poisoning. This is the most likely explanation for cardiomyopathy[26].

(3) Mitochondrial toxicity: CO causes inhibition of cytochrome c oxidase level at the mitochondrial chain, decrease of glutathione concentrations and of ATP generation [27].

(4) Toxic myocarditis due to high levels of CO: similar to what is seen in cases of severe scorpion envenomation [28].

#### **Metals**

Heavy metals, as cadmium, lead, mercury and arsenic, with multiple mechanisms (such as DNA damage and lipid peroxidation) can damage the cardiovascular system[29].

#### **Cadmium (Cd):**

Cadmium is a strong cardiotoxic heavy metal in the environment, which can be produced through chemical fertilizers, batteries and sewage [30]. Other studies have shown that cadmium toxicity is caused by cell apoptosis, DNA damage and oxidative stress. Cd toxicity can cause cardiotoxicity, hypertension and myocardial diseases such as atherosclerosis, hypertension, myocardial infarction and others. Cd poisoning increases antioxidant (glutathione, glutathione peroxidase, superoxide dismutase and catalase). It also decreases enzymatic activities of Cu,Zn-SOD [31].

#### **Mercury (Hg):**

Mercury toxicity was related to the CNS. However, increasing evidence suggests that methyl mercury exposure may increase the risk of adverse cardiovascular effects on populations . Hg-mediated vascular effects result in elevated oxidative stress, inflammation and decrease oxidative defense. Increased stress conditions and minimal protection this leads to thrombosis and mitochondrial dysfunction. Pathological findings related to mercury exposure and changes in lipid distribution included atherosclerosis, myocardial infarction and cardiovascular disease [31,32].

#### **Lead (Pb):**

Exposure to Pb can cause changes in systolic blood pressure, which can increase up to a factor of two in the range of 0.6 to 1.25 mm Hg. Pb exposure is associated with an increased incidence of clinical cardiovascular abnormalities such as coronary heart disease, stroke, peripheral arterial disease, left ventricular hypertrophy and changes in cardiac rhythm [33]. The contribution of Pb to cardiovascular diseases remains unclear

#### **Digitalis Toxicity:**

Digoxin is a well-known cardiac glycoside and one of the oldest drugs used today in cardiovascular disorder and its toxicity is very common due to narrow therapeutic index [34]. Digitalis normal mechanism of action includes: 1) inhibition of Na<sup>+</sup>/K<sup>+</sup> ATPase increasing sodium

intracellularly. This increased Na is shifted extracellularly in exchange with calcium ions. Increased intracellular Ca<sup>2+</sup> enhance myocardial contractility. 2) Increased intracellular Ca<sup>2+</sup> concentration increases cardiac contractility. 3) In toxic doses, intracellular calcium elevates further and triggers afterdepolarizations. This increases the risk of arrhythmias while shortening the refractory period and increasing automaticity 4) Digoxin also has neurohormonal effects, which increases parasympathetic tone. Increased vagal tone leads to stronger atrioventricular nodal blockade, leading to more uncontrolled arrhythmia. and increasing the myocardial refractory period through vagal tone stimulation[35]. Therefore, digitalis toxicity can cause variable types of arrhythmias such as; supraventricular and ventricular tachycardia, atrial fibrillation and flutter, ventricular fibrillation, extrasystole and heart block [36]. There are multiple factors that could increase incidence of digitalis toxicity including; renal insufficiency, patients with advanced age, MI and thyroid disorders, electrolyte imbalance and there are also medications which enhance digitalis toxicity like; diuretics, amiodarone, beta-blockers, benzodiazepines, calcium channel blockers, macrolide antibiotics, propylthiouracil and amphotericin [37].

#### **Conclusion:**

Toxic agents have a very harmful effect on the heart producing cardiomyopathy and heart failure. A lot of drugs and environmental toxins can produce cardiotoxicity including; anti-cancer drugs, anti-diabetic drugs, cocaine, ethanol, CO, and heavy metals. Mechanisms by which these agents produce cardiomyopathy are very complicated and include many factors such as mitochondrial toxicity. Eventually all the mechanism lead to increase work rate of the heart as compensation for degeneration leading to heart failure. The main way to prevent this condition is isolation of patient from toxic agents and treat the cardiovascular diseases produced.

**Conflicts of interests:** The Authors declare that there are no conflicts of interests.

**Financial Disclosure:** None

#### **Acknowledgments**

We appreciate the educational and technical support from teaching staff in the elective courses "Scientific publishing I and II, Faculty of Medicine Zagazig University". We appreciate the efforts of our supervisor Prof. Dr. Manar Hamed Arafa; Forensic medicine and clinical toxicology department, Faculty of medicine, Zagazig University.

We appreciate the participation of our colleague Ahmed Khaled Mohamed; Faculty of medicine, Zagazig University.

#### **REFERENCES**

1. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease, professional edition e-book: Elsevier health sciences; 2014.
- 2-Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med.* 1979;91(5):710-717. doi:10.7326/0003-4819-91-5-710.
- 3-Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: Focus on cardiovascular effects and outcomes. *Cardiovasc Diabetol.* 2015;14(1). doi:10.1186/s12933-015-0294-0.
- 4-Higgins AY, O'Halloran TD, Chang JD. Chemotherapy-induced cardiomyopathy. *Heart Fail Rev.* 2015;20(6):721-730. doi:10.1007/s10741-015-9502-y.
- 5- Menna P, Salvatorelli E, Minotti G. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival. *Chem Res Toxicol.* 2010;23(1):6-10. doi:10.1021/tx9003424
- 6-Hudis CA. Trastuzumab — mechanism of action and use in clinical practice. *N Engl J Med.* 2007;357(1):39-51. doi:10.1056/nejmra043186
- 7-Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. *J Clin Oncol.* 2005;23(13):2900-2902. doi:10.1200/jco.2005.05.827
- 8-Patanè S. Cardiotoxicity: Cisplatin and long-term cancer survivors. *Int J Cardiol.* 2014;175(1):201-202. doi:10.1016/j.ijcard.2014.04.238
- 9-Zhao X, Feng T, Chen H, Shan H, Zhang Y, Lu Y, Yang B. Arsenic trioxide-induced apoptosis in H9C2 cardiomyocytes: Implications in Cardiotoxicity. *Basic Clin Pharmacol Toxicol.* 2008;102(5):419-425. doi:10.1111/j.1742-7843.2007.00150.x
- 10-Rossato LG, Costa VM, Vilas-Boas V, de Lourdes Bastos M, Rolo A, Palmeria C, Remião F. Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9C2 cells as an earlier event. *Cardiovasc Toxicol.* 2013;13(4):413-425. doi:10.1007/s12012-013-9224-0
- 11-Rossato LG, Costa VM, Dallegrave E, Arbo M., Silva R, Ferreira R, et al. Mitochondrial cumulative damage induced by mitoxantrone: Late onset cardiac energetic impairment. *Cardiovasc Toxicol.* 2013;14(1):30-40. doi:10.1007/s12012-013-9230-2
- 12-Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. *Diabetologia.* 1995;38(1):116-121. doi:10.1007/bf02369361
- 13-Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, Mackay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. *Diabetes.* 1998;47(3):345-351. doi:10.2337/diabetes.47.3.345
- 14- Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. *Diabetes*

- Metab Res Rev. 2002;18 Suppl 2:S23-S29. doi:10.1002/dmrr.252
- 15-DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. *Ann Intern Med.* 2000;133(1):73. doi:10.7326/0003-4819-133-1-200007040-00016.
- 16-Phillips K, Luk A, Soor GS, Abraham JR, Leong S, Butany J. Cocaine cardiotoxicity. *Am J Cardiovasc Drugs.* 2009;9(3):177-196. doi:10.1007/bf03256574
- 17-Wiener RS, Lockhart JT, Schwartz RG. Dilated cardiomyopathy and cocaine abuse. report of two cases. *Am J Med.* 1986;81(4):699-701. doi:10.1016/0002-9343(86)90559-0
- 18-Kazimir M, Talano JV, Hayes S. Cocaine-Related Cardiomyopathy. *Medscape.* December 13, 2020. <https://emedicine.medscape.com/article/152535>
- 19-Nguyen VQ, Celebi MM, Suleman A, Sander GE. Dilated Cardiomyopathy. *Medscape.* March 2, 2021. <https://emedicine.medscape.com/article/152696>
- 20-Guzzo-Merello G. Alcoholic cardiomyopathy. *World J Cardiol.* 2014;6(8):771. doi:10.4330/wjc.v6.i8.771
- 21-Gavazzi A, De Maria R, Parolini M, Porcu M. Alcohol abuse and dilated cardiomyopathy in men. *Am J Cardiol.* 2000;85(9):1114-1118. doi:10.1016/s0002-9149(00)00706-2
- 22-Fernández-Solà J. The effects of ethanol on the heart: Alcoholic cardiomyopathy. *Nutrients.* 2020;12(2):572. doi:10.3390/nu12020572
- 23-Raub JA, Mathieu-Nolf M, Hampson NB, Thom SR. Carbon monoxide poisoning — a public health perspective. *Toxicology.* 2000;145(1):1-14. doi:10.1016/s0300-483x(99)00217-6
- 24-Kalay N, Ozdogru I, Cetinkaya Y, Eryol N K, Dogan A, Gul I, et al . Cardiovascular effects of carbon monoxide poisoning. *Am J Cardiol.* 2007;99(3):322-324. doi:10.1016/j.amjcard.2006.08.030
- 25-Fitzgerald RS, Dehghani GA, Kiihl S. Autonomic control of the cardiovascular system in the cat during hypoxemia. *Auton Neurosci.* 2013;174(1-2):21-30. doi:10.1016/j.autneu.2012.11.005
- 26-Tritapepe L, Macchiarelli G, Rocco M, Scopinaro F, Schillaci O, Martuscelli, Motta PM. Functional and ultrastructural evidence of myocardial stunning after acute carbon monoxide poisoning. *Crit Care Med.* 1998;26(4):797-801. doi:10.1097/00003246-199804000-00034
- 27- Suner S, Jay G. Carbon monoxide has direct toxicity on the myocardium distinct from effects of hypoxia in an ex vivo rat heart model. *Acad Emerg Med.* 2008;15(1):59-65. doi:10.1111/j.1553-2712.2007.00012.x
- 28-Cupo P, Jurca M, Azevedo-Marques MM, Oliveira JS, Hering SE. Severe scorpion envenomation in Brazil: Clinical, laboratory and Anatomopathological Aspects. *Rev Inst Med Trop Sao Paulo.* 1994;36(1):67-76. doi:10.1590/s0036-46651994000100011
- 29-Ansari MN, Ganaie MA, Rehman NU, Alharthy KM., Khan TH, Imam F ,et al. . Protective role of roflumilast against cadmium-induced cardiotoxicity through inhibition of oxidative stress and NF-KB signaling in rats. *Saudi Pharm J.* 2019;27(5):673-681. doi:10.1016/j.jsps.2019.04.002
- 30- Genchi G, Sinicropi MS, Carocci A, Lauria G, Catalano A. Response to Comment on Giuseppe Genchi et al. Mercury Exposure and Heart Diseases. *Int. J. Environ. Res. Public Health* 2017, 14, 74. *Int J Environ Res Public Health.* 2017;14(7):761. Published 2017 Jul 12. doi:10.3390/ijerph14070761
- 31-Hartley A, Haskard D, Khamis R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis – novel insights and future directions in diagnosis and therapy. *Trends Cardiovasc Med.* 2019;29(1):22-26. doi:10.1016/j.tcm.2018.05.010
- 32-Lara-Guzmán OJ, Gil-Izquierdo Á, Medina S, Osorio E., Álvarez-Quintero R., Zuluaga N, et al. Oxidized LDL triggers changes in oxidative stress and inflammatory biomarkers in human macrophages. *Redox Biol.* 2018;15:1-11. doi:10.1016/j.redox.2017.11.017
- 33-Adal A, Wiener SW. Heavy Metal Toxicity Medication. *Medscape.* December 31,2020. <https://emedicine.medscape.com/article/814960>
- 34-Gurel E, Karvar S, Yucesan B, Eker I, Sameeullah M. An overview of Cardenolides in digitalis - more than a cardiotoxic compound. *Compound. Curr Pharm Des.* 2018;23(34). doi:10.2174/1381612823666170825125426
- 35--Burns E, Buttner R. Digoxin Toxicity. *Life in the Fastlane.* July 18, 2021. <https://litfl.com/digoxin-toxicity-ecg-library> .
- 36- Rehman R, Hai O. Digitalis Toxicity. *Treasure Island (FL): StatPearls Publishing.* November 28, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK459165/>
- 37- William Dec G. Digoxin remains useful in the management of. *Chronic Heart Failure. Med Clin North Am.* 2003;87(2):317-337. doi:10.1016/s0025-7125(02)00172-4

**To Cite:**

Khaled, A., Mohamed, M., Gheith, A., Mohamed, H., abdelatif, G., Fouad, R., Tantawy, A., Melad, E., Magdy, H., Elkordi, Y., Mohamed, A. Mechanism of actions of some common toxic agents causing toxic cardiomyopathy. *Zagazig University Medical Journal*, 2022; (1184-1188): -. doi: 10.21608/zumj.2022.125953.2492